Solid phase synthesis of 1,3,5-trisubstituted pyridin-2-ones

Tetrahedron Letters

Volumn 40, Issue 12, 1999, Pages 2227-2230

  Linn, James A ^a   Gerritz, Samuel W ^a   Handlon, Anthony L ^a   Hyman, Clifton E ^a   Heyer, Dennis ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPYRIDINE; AMINE; ESTER DERIVATIVE; HALOACID; METHYL GROUP; PYRIDONE DERIVATIVE; TRIFLUOROACETIC ACID;

ALKYLATION; AMINATION; ARTICLE; CHEMICAL BOND; CHEMICAL REACTION; DRUG SYNTHESIS; SOLID STATE;

EID: 0033582966     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(98)02628-8     Document Type: Article

References (22)

1. 1. (a) Sanderson, P. E. J. Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-199. Publisher: American Chemical Society, Washington, D. C.
2. (b) Sanderson, P. E. J.; Dyer, D. L.; Naylor-Olsen, A. M.; Vacca, J. P.; Gardell, S. J.; Lewis, S. D.; Lucas, B. J., Jr.; Lyle, E. A.; Lynch, J. J., Jr.; Mulichak, A. M. Bioorg. Med. Chem. Lett. 1997, 7, 1497.
3. (c) Bantick, J. R.; Beaton, H. G.; Cooper, S. L.; Hill, S.; Hirst, S. C.; McInally, T.; Spencer, J.; Tinker, A. C.; Willis, P. A. Bioorg. Med. Chem. Lett. 1994, 4, 121.
4. (d) Jourdan, F.; Renault, J.; Fossey, C.; Bureau, R.; Laduree, D.; Robba, M.; Aubertin, A. M.; Kirn, A. Antiviral Chem. Chemother. 1997, 8, 161.
5. (e) Dollé, V.; Fan, E.; Nguyen, C. H.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Jamieson, G.; Tarrago-Litvak, L.; Bisagni, E. J. Med. Chem. 1995, 38, 4679.
6. (f) Kosulina, T. P.; Kaigorodova, E. A.; Kul'nevich, V. G.; Sapunov, A. Y.; Govorova, S.A. Khim.-Farm. Zh. 1997, 31, 30.
7. (g) Dannhardt, G.; Meindl, W.; Schober, B. D.; Kappe, T. Eur. J. Med. Chem. 1991, 26, 599.
8. (h) McNamara, D. J.; Cook, P. D.; Allen, L. B.; Kehoe, M. J.; Holland, C. S.; Teepe, A. G. J. Med. Chem. 1990, 33, 2006.
9. (i) Cook, P. D.; Day, R. T.; Robins, R. K. J. Heterocycl. Chem. 1977, 14, 1295.
10. (j)Margolin, S. B. Substituted pyridones for inhibition of tumor necrosis factor α, and use for inhibition of pathophysiological effects of excess tumor necrosis factor α. PCT Int. Appl., 63 pp. WO 9710712 A1 970327.
11. (k) Hartmann, R. W.; Reichert, M.; Göhring, S. Eur. J. Med. Chem. 1994, 29, 807.
12. 2. (a) Katritzky, A. R.; Belyakov, S. A.; Sorochinsky, A. E.; Henderson, S. A.; Chen, J. J. Org. Chem. 1997, 62, 6210.
13. (b) Sato, T.; Yoshimatsu, K.; Otera, J. Synlett 1995, 8, 845.
14. (c) Comins, D. L.; Jianhua, G. Tetrahedron Lett. 1994, 35, 2819.
15. (d) Cocco, M. T.; Congiu, C.; Maccioni, A.; Onnis, V. J. Heterocycl. Chem. 1992, 29, 1631.
16. 3. Chen, C.; Mcdonald, I. A.; Munoz, B. Tetrahedron Lett. 1998, 39, 217.
17. 4. Macrocrowns were purchased from Chiron Mimotopes Pty. Ltd., Clayton, Victoria, Australia.
18. 1H-NMR and electrospray (+)-ion mass spectral data were consistent with the structure.
19. 2O (0.1% TFA) gradient over 20 min.].
20. + 551 m/z for the major peak.
21. 8. Green, M.; Herman, J. Tetrahedron Lett. 1990, 31, 5851.
22. 1H-NMR were identical to 7 prepared from the TFAA experiment described in ref. 6.